In 2010, researchers in Europe linked use of Depakote during the first trimester of pregnancy with six types of birth defect. The research, published in the New England Journal of Medicine (6/10/10), involved analysis of 98,000 pregnancies to determine whether or not the use of Depakote during pregnancy was associated with an increased risk of birth defects.
According to researchers, whose data was reported on by ABC News (6/10/10), the risk of spina bifida—a serious birth defect—increased more than 12 times when mothers used Depakote during the first trimester. Other birth defects that increased with use of Depakote were atrial septal defect, cleft palate, hypospadias, craniosynostosis and polydactyly (more than five fingers on one hand). Each of these defects was increased by between two and seven times when the infants were exposed to Depakote prior to birth.
The study did not show whether it was the use of Depakote that increased the risk or the condition the Depakote was used to treat that increased the risk of birth defects. Information from the US Food and Drug Administration (FDA), however, indicates that use of Depakote while pregnant is linked to birth defects. The information label for Depakote states, "Data suggest that there is an increased incidence of congenital malformations associated with the use of valproate [Depakote] by women with seizure disorders during pregnancy when compared to the incidence in women with seizure disorders who do not use antiepileptic drugs during pregnancy."
The strongest risk is reportedly of neural tube defects, including spina bifida, according to the FDA.
READ MORE DEPAKOTE BIRTH DEFECT LEGAL NEWS
Depakote is approved to treat epilepsy, manic episodes associated with bipoloar disorder and migraine headaches. Abbott reportedly marketed the drug for agitation and aggression in the elderly and other unapproved uses. Although it is not illegal for a doctor to prescribe a drug for an off-label use, it is illegal for a company to market the drug for unapproved uses.